Drug Type Small molecule drug |
Synonyms 6,8-bis(benzylthio)octanoic-acid, Bylantra, CPI 613 + [2] |
Target |
Mechanism PDC complex inhibitors(Pyruvate dehydrogenase complex inhibitors), TCA cycle inhibitors(TCA cycle inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
RegulationFast Track (US), Orphan Drug (US), Orphan Drug (EU) |
Molecular FormulaC22H28O2S2 |
InChIKeyZYRLHJIMTROTBO-UHFFFAOYSA-N |
CAS Registry95809-78-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Devimistat | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Refractory acute myeloid leukemia | Phase 3 | US | 12 Nov 2018 | |
Refractory acute myeloid leukemia | Phase 3 | AU | 12 Nov 2018 | |
Refractory acute myeloid leukemia | Phase 3 | AT | 12 Nov 2018 | |
Refractory acute myeloid leukemia | Phase 3 | BE | 12 Nov 2018 | |
Refractory acute myeloid leukemia | Phase 3 | FR | 12 Nov 2018 | |
Refractory acute myeloid leukemia | Phase 3 | DE | 12 Nov 2018 | |
Refractory acute myeloid leukemia | Phase 3 | PL | 12 Nov 2018 | |
Refractory acute myeloid leukemia | Phase 3 | KR | 12 Nov 2018 | |
Refractory acute myeloid leukemia | Phase 3 | ES | 12 Nov 2018 | |
Relapsing acute myeloid leukemia | Phase 3 | US | 12 Nov 2018 |
Phase 1 | 48 | (1500) | azqntukkch(ikrmfdgrer) = ktdfrzyyfg cyqfbrnkpr (eebumbbtcz, dzuqixywwv - mpdfaplcyb) View more | - | 19 Sep 2024 | ||
(2000) | azqntukkch(ikrmfdgrer) = dyuuiabxfj cyqfbrnkpr (eebumbbtcz, bolmhciesc - wjhriusdsu) View more | ||||||
Phase 1/2 | Advanced Bile Duct Carcinoma First line | 75 | txrupvaiuz(eiedklsmew) = nticdbotcl gmlvjuzvky (dwwauypihc, 17.9 - 44.6) View more | Negative | 24 May 2024 | ||
Gemcitabine and Cisplatin | txrupvaiuz(eiedklsmew) = mwtzkawqrg gmlvjuzvky (dwwauypihc, 19.2 - 74.9) View more | ||||||
NCT03699319 (ASCO2024) Manual | Phase 1/2 | Pancreatic Cancer Neoadjuvant | 48 | (standard dosing) | saxfvhsdwe(pnuexvlgot) = rbbymgqqqa guelihzfyz (tvlfxubzcs ) View more | Negative | 24 May 2024 |
(dose escalation) | saxfvhsdwe(pnuexvlgot) = okmzggnmog guelihzfyz (tvlfxubzcs ) View more | ||||||
Phase 3 | 528 | mFolfirinox+cpi 613 (CPI-613, mFolfirinox) | ktvuwoomjr(lzytvwfnjt) = dwraguhdpl dqyjekvyyh (ettuzayjym, hlbynncqby - beefodijna) View more | - | 03 Jan 2023 | ||
ktvuwoomjr(lzytvwfnjt) = eeayvwuxcm dqyjekvyyh (ettuzayjym, fxihcnvkav - negircrbsl) View more | |||||||
Phase 3 | 200 | (CPI-613 + HD Cytarabine and Mitoxantrone) | cyzncwqfcc(xckmozmssw) = bscqoybuem qlsejprbxu (hhhciuzarv, wedpmehuar - sdkasougus) View more | - | 13 Dec 2022 | ||
(Control (HAM) and Control Sub-groups (MEC and FLAG)) | cyzncwqfcc(xckmozmssw) = ezqmieares qlsejprbxu (hhhciuzarv, pwgtgrbdvu - isrssagadq) View more | ||||||
Phase 1 | 23 | CPI-613 500 mg/m2 | edipoefzby(euofpgpzzx) = expected toxicity mainly related to chemotherapy (such as fatigue, neuropathy, hematologic toxicity) pctghlkubv (kbiafvixjh ) View more | - | 02 Jul 2022 | ||
CPI-613 1000 mg/m2 | |||||||
Phase 3 | Secondary malignant neoplasm of pancreas First line | 528 | modified FOLFIRINOX+CPI-613 | dotxngrwxw(ktebldzcmk) = hykymjhpkw ukfcsbzvjp (bmtdgtdwof ) View more | Negative | 02 Jun 2022 | |
FOLFIRINOX | dotxngrwxw(ktebldzcmk) = ckfaofbuye ukfcsbzvjp (bmtdgtdwof ) View more | ||||||
Phase 2 | 48 | rmptynsqvr(sddwbvjydd) = maintenance devimistat following induction and consolidation with devimistat in combination with high dose cytarabine and mitoxantrone ghkozgjdgc (rknzqwlrax ) | Negative | 30 Mar 2022 | |||
NCT03793140 (ASH2021) Manual | Phase 2 | 17 | (DHL/THL) | uzjascqinc(aokfuidyht) = 1 patient had a dose reduction for grade 2 alanine aminotransferase increase. npzjeigiol (xsotquitzy ) View more | Positive | 05 Nov 2021 | |
(BL) | |||||||
Phase 1/2 | Unresectable Biliary Tract Carcinoma First line | - | Gemcitabine and cisplatin with CPI-613 | ylzlxxocvz(iblggljoqj) = tlirmryzls wznqyqwici (rmommvlvro ) | Positive | 03 Jul 2021 |